Description: Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier (GEC), which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignant GEC test for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Home Page: www.veracyte.com
VCYT Technical Analysis
6000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
650 243 6300
Officers
Name | Title |
---|---|
Ms. Bonnie H. Anderson | Co-Founder & Exec. Chairwoman |
Mr. Marc A. Stapley | CEO & Director |
Ms. Rebecca Chambers | Exec. VP & CFO |
Dr. Giulia C. Kennedy Ph.D. | Global Chief Scientific Officer & Chief Medical Officer |
Dr. Tina S. Nova Ph.D. | Pres of CLIA U.S. Bus. |
Ms. Beverly Jane Alley CPA | VP & Corp. Controller |
Mr. Jonathan Wygant | VP & Chief Accounting Officer |
Mr. Steven French | Sr. VP & Chief Information Officer |
Ms. Annie McGuire | Sr. VP & Gen. Counsel |
Ms. Tracy Morris | VP of Global Corp. Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.9941 |
Price-to-Sales TTM: | 7.1658 |
IPO Date: | 2013-10-30 |
Fiscal Year End: | December |
Full Time Employees: | 761 |